ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.24
+1.35%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.15
From 52W high−60.60%
Volume21327.00
Market cap$32.72M
P/E (TTM)—
P/S (TTM)1.0x
Div yield—
Key dataSep 18, 2026
Open
$5.15
From 52W high
−60.60%
Volume
21327.00
Market cap
$32.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
37.9
MomentumView details →
1D Return
+1.35%
YTD Return
−45.49%
SummaryUpdated Jun 1, 2026
Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company went public in October 2020 and focuses on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Since its inception, Aligos has built a pipeline of drug candidates targeting chronic hepatitis B and non-alcoholic steatohepatitis (NASH), with several compounds currently in various phases of clinical trials.
Similar companies
Latest newsMore news →
Aligos Therapeutics amended its lease with Britannia Biotech Gateway Limited Partnership, extending the term to March 31, 2034 with escalating rent, a 10-month abatement, and an early termination option.5d agoAligos Therapeutics reported Q2 2026 financial results with revenue of $27.8 million and a net loss of $1.5 million.46d ago